SCHEMBL386205

SCHEMBL386205

[CH]=CCN(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543501 0.72
SCHEMBL3945142 0.67
SCHEMBL317785 0.67 KDM4E (0.36)
SCHEMBL235759 0.67 KDM4E (0.36)
SCHEMBL1329678 0.65
SCHEMBL293591 0.64
Ammonia Solution, Strong SCHEMBL9748105 0.64 KDM4E (0.34)
Hydrochloric Acid SCHEMBL10694332 0.64 KDM4E (0.34)
Hydrochloric Acid SCHEMBL10694337 0.64 KDM4E (0.34)
SCHEMBL2644847 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 EP claimed
US-20230303584-A1 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF CIT THERAPEUTICS LLC 2023-09-28 US claimed
WO-2023137297-A2 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROLE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-07-20 WO claimed
WO-2023004376-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-01-26 WO claimed
CN-114728009-A Preventing or treating diseases and disorders associated with tissue damage 李晓祥 2022-07-08 CN claimed
WO-2021150918-A1 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF ONCOVALENT THERAPEUTICS INC. (US) 2021-07-29 WO claimed
WO-2021024141-A1 PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE LI XIAOXIANG (CN) 2021-02-11 WO claimed
CN-102993250-B -9-deoxidation-9A-azepine-9A-the a-homoerythromycin A derivatives that C-3 replaces Luoyang Huizhong Animal Medicine Co., Ltd. (CN) 2016-02-10 CN claimed
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP claimed
CN-102993250-A C-3 substituted-9-deoxidized-9A-aza-9A-high erythromycin A derivative LUOYANG HUIZHONG ANIMAL MEDICINE CO LTD 2013-03-27 CN claimed
US-20020156026-A1 C-4\"-substituted macrolide derivatives BRONK BRAIN SCOTT (US) 2002-10-24 US claimed
US-6407074-B1 BACTERICIDES, ANTIBIOTICS PFIZER INC 2002-06-18 US claimed
US-20020061858-A1 4\"-substituted-9-deoxo-9A-AZA-9A-homoerythromycin a derivatives PFIZER INC. 2002-05-23 US claimed
EP-1024145-A2 Novel azalides and methods of making same Pfizer Products Inc. (US) 2000-08-02 EP claimed
CN-1259955-A C-4'-substituted macrolide derivatives PFIZER PROD INC (US) 2000-07-12 CN claimed
CN-1259136-A 4' -substituted-9-deoxo-9A-aza-9A-homoerythromycin A derivatives PFIZER PROD INC (US) 2000-07-05 CN claimed
EP-0988309-A1 C-4''-SUBSTITUTED MACROLIDE DERIVATIVES Pfizer Products Inc. (US) 2000-03-29 EP claimed
EP-0988310-A1 4\"-SUBSTITUTED-9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVES Pfizer Products Inc. (US) 2000-03-29 EP claimed
WO-1998056801-A1 C-4''-SUBSTITUTED MACROLIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-12-17 WO claimed
WO-1998056802-A1 4'-SUBSTITUTED-9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-12-17 WO claimed